DE3780361T2 - Gastroprotektives verfahren und zusammensetzungen. - Google Patents
Gastroprotektives verfahren und zusammensetzungen.Info
- Publication number
- DE3780361T2 DE3780361T2 DE8787103264T DE3780361T DE3780361T2 DE 3780361 T2 DE3780361 T2 DE 3780361T2 DE 8787103264 T DE8787103264 T DE 8787103264T DE 3780361 T DE3780361 T DE 3780361T DE 3780361 T2 DE3780361 T2 DE 3780361T2
- Authority
- DE
- Germany
- Prior art keywords
- agonist
- gastric
- nsaid
- beta
- adrenergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 16
- 230000002178 gastroprotective effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 title description 3
- 230000002496 gastric effect Effects 0.000 claims description 41
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 31
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 30
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 29
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 24
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 19
- 229960002657 orciprenaline Drugs 0.000 claims description 16
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 15
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 14
- 229940039009 isoproterenol Drugs 0.000 claims description 14
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229960002052 salbutamol Drugs 0.000 claims description 11
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 8
- 229960000195 terbutaline Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229960001634 ritodrine Drugs 0.000 claims description 5
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 claims description 5
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 4
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004620 bitolterol Drugs 0.000 claims description 4
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 claims description 4
- PHSMOUBHYUFTDM-UHFFFAOYSA-N colterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(O)=C1 PHSMOUBHYUFTDM-UHFFFAOYSA-N 0.000 claims description 4
- 229950004306 colterol Drugs 0.000 claims description 4
- 229960001022 fenoterol Drugs 0.000 claims description 4
- 229960001268 isoetarine Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 201000006549 dyspepsia Diseases 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 230000003902 lesion Effects 0.000 description 59
- 210000002784 stomach Anatomy 0.000 description 35
- 238000012360 testing method Methods 0.000 description 31
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 30
- 241000282472 Canis lupus familiaris Species 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 208000025865 Ulcer Diseases 0.000 description 16
- 229960000905 indomethacin Drugs 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 12
- 229960001380 cimetidine Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 239000000523 sample Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 206010037549 Purpura Diseases 0.000 description 8
- 230000001262 anti-secretory effect Effects 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 206010034754 petechiae Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 238000013289 male long evans rat Methods 0.000 description 5
- 210000005070 sphincter Anatomy 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010065713 Gastric Fistula Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002627 tracheal intubation Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000218594 Picea pungens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XCIDNCPEXLYEOP-UHFFFAOYSA-N 2-oxo-1h-pyrazine-3-carbaldehyde Chemical class OC1=NC=CN=C1C=O XCIDNCPEXLYEOP-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001433070 Xiphoides Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000002599 gastric fundus Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium meclofenamate (anhydrous) Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85854286A | 1986-04-29 | 1986-04-29 | |
| US07/011,792 US4965065A (en) | 1986-04-29 | 1987-02-06 | Gastroprotective process and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3780361D1 DE3780361D1 (de) | 1992-08-20 |
| DE3780361T2 true DE3780361T2 (de) | 1992-12-17 |
Family
ID=26682793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8787103264T Expired - Lifetime DE3780361T2 (de) | 1986-04-29 | 1987-03-06 | Gastroprotektives verfahren und zusammensetzungen. |
Country Status (5)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043358A (en) * | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
| JPH01197444A (ja) * | 1986-03-04 | 1989-08-09 | Bristol Myers Co | 非ステロイド系抗炎症組成物によって生じる消化管損傷に対するβ−アドレナリン作用薬とある種のヒスタミンＨ↓１−および／またはＨ↓２−受容体遮断薬との組合せの効果 |
| EP0320550A1 (en) * | 1987-12-18 | 1989-06-21 | Bristol-Myers Company | Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent |
| EP0321613A1 (en) * | 1987-12-18 | 1989-06-28 | Bristol-Myers Company | The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| US5071842A (en) * | 1988-10-14 | 1991-12-10 | Bristol-Myers Squibb Company | Aspirin-containing composition including diphenhydramine and an alkalizing agent to reduce gastrointestinal injury potential |
| EP0509036B1 (en) * | 1990-01-05 | 1996-03-27 | Sepracor, Inc. | Optically pure r(-) albuterol for treating asthma |
| EP0556880A3 (en) * | 1992-01-22 | 1993-10-27 | Glaxo Group Limited | Medical use for atypical beta-adrenoceptor agonists |
| IS4198A (is) * | 1993-08-13 | 1995-02-14 | Somatogen, Inc | Meðferð vegna aukaverkana sem tengjast gjöf á utanfrumublóðrauða |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| ATE474559T1 (de) * | 2001-06-01 | 2010-08-15 | Pozen Inc | Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| EP1613266A4 (en) * | 2003-04-15 | 2009-05-06 | Theraquest Biosciences Llc | METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF |
| DE10356112A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
| US7488107B2 (en) * | 2005-08-18 | 2009-02-10 | General Electric Company | Method and apparatus to detect and correct alignment errors in x-ray systems used to generate 3D volumetric images |
| WO2009043355A2 (en) * | 2007-10-02 | 2009-04-09 | Johansson Paer | SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH |
| MX2011002515A (es) * | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita. |
| EA201290026A1 (ru) | 2009-06-25 | 2012-07-30 | Астразенека Аб | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) |
| WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4025624A (en) * | 1975-11-18 | 1977-05-24 | A. H. Robins Company, Incorporated | Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy |
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
-
1987
- 1987-02-06 US US07/011,792 patent/US4965065A/en not_active Expired - Lifetime
- 1987-03-06 EP EP87103264A patent/EP0248150B1/en not_active Expired - Lifetime
- 1987-03-06 ES ES87103264T patent/ES2042511T3/es not_active Expired - Lifetime
- 1987-03-06 DE DE8787103264T patent/DE3780361T2/de not_active Expired - Lifetime
-
1992
- 1992-07-16 GR GR920401474T patent/GR3005208T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2042511T3 (es) | 1993-12-16 |
| EP0248150B1 (en) | 1992-07-15 |
| EP0248150A1 (en) | 1987-12-09 |
| DE3780361D1 (de) | 1992-08-20 |
| GR3005208T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-05-24 |
| US4965065A (en) | 1990-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3780361T2 (de) | Gastroprotektives verfahren und zusammensetzungen. | |
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| DE69003229T2 (de) | Entzündungshemmendes Mittel in einer Zusammensetzung. | |
| DE69006684T2 (de) | Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit. | |
| DE3686362T2 (de) | Verfahren zur behandlung von magen-darmstoerungen. | |
| DE3874917T2 (de) | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. | |
| DE2907215A1 (de) | Feste depotarzneimittelpraeparate und verfahren zu deren herstellung | |
| US5043358A (en) | Gastroprotective process | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| CH647409A5 (de) | Pharmazeutische zubereitung zur behandlung und verhinderung von entzuendlichen darmkrankheiten, salze der 5,5'-azobissalicylsaeure und verfahren zur herstellung dieser salze. | |
| DE69029732T2 (de) | Bivalente metallsalze von indomethacin | |
| DE2936078A1 (de) | Synthetisches magnesiumaluminiumsilikat, verfahren zu seiner herstellung und praeparat enthaltend dasselbe | |
| DE2040578C3 (de) | Analgetisch, antiinflammatorisch und antiulcerogen wirkendes Arzneimittel | |
| DE3918320A1 (de) | Verwendung von somatostatinanalogen und somatostatinderivaten zur behandlung von arthritis | |
| DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
| DE1670005C2 (de) | β-(4,5-Diphenyloxazol-2-yl)-propionsäure oder ein pharmazeutisch verträgliches Salz davon, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten | |
| DE69226525T2 (de) | Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre | |
| DE3226178A1 (de) | Mittel enthaltend n-acetyl-p-aminophenol und ein antacidum | |
| DE3152319T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3213091A1 (de) | Verwendung von femoxetin oder einem pharmazeutisch vertraeglichen salz davon zur steuerung und verminderung von appetit und gewicht | |
| EP0624373B1 (de) | Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung | |
| DE69626301T2 (de) | Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen | |
| DE69721077T2 (de) | Verwendung von 2-methoxyphenyl-1-methyl-5p-methyl-benzoylpyrrol-2-acetamido-acetat zur herstellung eines antientzündungsmittels mit vorbeugung von magenhypersekretion und nierenfunktionsstörung | |
| DE1043587B (de) | Verfahren zur Herstellung eines Appetitzueglers | |
| AU594125B2 (en) | Gastroprotective process and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |